{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Testicular+Cancer+AJCC+v8&page=2", "query": { "condition": "Stage II Testicular Cancer AJCC v8", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Testicular+Cancer+AJCC+v8&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T03:22:56.300Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03132532", "title": "Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Lung Non-Small Cell Carcinoma", "Stage II Lung Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Proton Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-07-31", "completion_date": "2023-12-23", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132532" }, { "nct_id": "NCT04562480", "title": "Radiation Therapy Before Surgery for Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Soft Tissue Sarcoma", "Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8", "Stage II Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2020-11-30", "completion_date": "2029-10-31", "has_results": true, "last_update_posted_date": "2026-02-04", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04562480" }, { "nct_id": "NCT04081389", "title": "Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Early-Stage Breast Carcinoma", "Estrogen Receptor Negative", "HER2/Neu Negative", "Progesterone Receptor Negative", "Prognostic Stage 0 Breast Cancer AJCC v8", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Celecoxib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Recombinant Interferon Alfa-2b", "type": "BIOLOGICAL" }, { "name": "Rintatolimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-12-06", "completion_date": "2023-02-27", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081389" }, { "nct_id": "NCT06855706", "title": "An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Stage II Fallopian Tube Cancer AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Primary Peritoneal Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8" ], "interventions": [ { "name": "Behavioral Intervention", "type": "BEHAVIORAL" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "OTHER" }, { "name": "Medical Device Usage and Evaluation", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Supportive Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2025-06-04", "completion_date": "2028-04-30", "has_results": false, "last_update_posted_date": "2026-01-06", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06855706" }, { "nct_id": "NCT05023967", "title": "Metformin and Nightly Fasting in Women With Early Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Breast Ductal Carcinoma In Situ", "Invasive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Extended Release Metformin Hydrochloride", "type": "DRUG" }, { "name": "Monitoring", "type": "OTHER" }, { "name": "Nutritional Assessment", "type": "OTHER" }, { "name": "Short-Term Fasting", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2023-04-04", "completion_date": "2026-12-16", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05023967" }, { "nct_id": "NCT04678414", "title": "Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Endometrial Carcinoma", "Female Reproductive System Disorder", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Stage I Uterine Corpus Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Ovarian Cancer AJCC v8", "Stage IA Uterine Corpus Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IC Ovarian Cancer AJCC v8" ], "interventions": [ { "name": "Healthcare Activity", "type": "BEHAVIORAL" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 1410, "start_date": "2019-04-01", "completion_date": "2027-02-02", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04678414" }, { "nct_id": "NCT03505736", "title": "Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage IA Breast Cancer AJCC v8", "Anatomic Stage IB Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Premenopausal", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage IA Breast Cancer AJCC v8", "Prognostic Stage IB Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8" ], "interventions": [ { "name": "Adenosine", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Regadenoson", "type": "DRUG" }, { "name": "Stress Management Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "55 Years", "sex": "FEMALE", "summary": "Up to 55 Years · Female only" }, "enrollment_count": 25, "start_date": "2018-06-21", "completion_date": "2020-03-05", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03505736" }, { "nct_id": "NCT05651594", "title": "Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage II Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Esophageal Adenocarcinoma AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Esophageal Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Metastatic Esophageal Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Unresectable Esophageal Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Propranolol Hydrochloride", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-03-07", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05651594" }, { "nct_id": "NCT03520283", "title": "Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer Survivor", "Stage I Colorectal Cancer AJCC v8", "Stage II Colorectal Cancer AJCC v8", "Stage IIA Colorectal Cancer AJCC v8", "Stage IIB Colorectal Cancer AJCC v8", "Stage IIC Colorectal Cancer AJCC v8", "Stage III Colorectal Cancer AJCC v8", "Stage IIIA Colorectal Cancer AJCC v8", "Stage IIIB Colorectal Cancer AJCC v8", "Stage IIIC Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Interview", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "System Support Mapping", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-05-29", "completion_date": "2020-02-06", "has_results": true, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03520283" }, { "nct_id": "NCT04164069", "title": "Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Metastatic Colorectal Carcinoma", "Stage IV Colorectal Cancer AJCC v8", "Stage IVA Colorectal Cancer AJCC v8", "Stage IVB Colorectal Cancer AJCC v8", "Stage IVC Colorectal Cancer AJCC v8", "Stage II Colon Cancer", "Stage II Rectal Cancer", "Stage III Colon Cancer", "Stage III Rectal Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Bile Duct Cancer", "Gastric Cancer", "Gall Bladder Cancer", "Small Bowel Adenocarcinoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Anne Noonan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2020-09-02", "completion_date": "2023-06-22", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-06-26T03:22:56.300Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04164069" } ] }